RheumNow Podcast – BandAids for Rheumatologists (5.14.2021)

Save

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com - a website for rheumatologists, by rheumatologists.

We love Rheumatology!

RheumNow Live 2021 Now Available for All

Save

RheumNow Live (RNL) for 2021 was held March 20 - 21 in Fort Worth, TX, and now all can partake in the meeting - by video, podcast or by signing up for Tuesday Nite Rheumatology (TNR).

NSAID Safety with COVID-19 Infection

Save

NSAIDs do not affect COVID outcomes; here we are nearly 16 months into the pandemic, and this is the common sense conclusion of a recent trial published in Lancet Rheumatology.

RheumNow Podcast – Falling or Falling in Love?

Save

Dr. Jack Cush reviews the best journal articles from the past week on RheumNow.com.

Drug Monitoring Ineffective with Infliximab Treatment

Save

The predictive value of therapeutic drug monitoring (TDM) while on biologics is debateable; gastroenterology routinely relies on TDM, while rheumatologists do not.

Results Disappoint for Fecal Transplant in Arthritis

Save

Fecal microbiota transplantation (FMT) showed disappointing results among patients with active psoriatic arthritis, a small randomized trial found.

RheumNow Podcast – Uppers and Downers

Save

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Predictors of Methotrexate Toxicity

Save

A metanalysis showed that while adverse events (AEs) are common when methotrexate is used in rheumatoid arthritis or inflammatory arthritis patients, serious AEs ranged from 2.1 to 9.5% and drug discontinuations ranged from 6.7% to 15.5%, mostly due to gastrointestinal events. 

Psoriatic Pregnancies Pose Risks to the Mother, Not Child

Save

A metanalysis of pregnancy outcomes in women with psoriasis and psoriatic arthritis finds an excess risk of adverse maternal events, but not adverse neonatal events.

This systematic review included 16 studies meeting inclusion criteria. 

Dual IL-17 Targeting is Effective but has More Candidiasis

Save

Bimekizumab (BIM) is a monoclonal antibody that targets both interleukin-17A and interleukin-17F, which as a biologic target has worked well in the management of psoriatic disease. The current issue of the NEJM has two reports wherein BIM was shown to be more effective than secukinumab and adalimumab in treating patients with moderate-to-severe plaque psoriasis; however, safety concerns arise. 

RheumNow Podcast – Coconspirators: RA and Lung Disease

Save

Dr. Jack Cush reviews and discusses more than a dozen news and journal articles from the past week on RheumNow.com.

Diagnostic Delay in Spondyloarthritis

Save

Literature review and metanalysis of many studies suggests that significant delay to diagnosis in axial spondyloarthritis (axSpA) exist, are longer than other rheumatic diseases and have not changed over time.

Increased Methotrexate Liver Disease in Psoriasis

Save

A Danish cohort study examined the risk of methotrexate related liver disease risk in patients with psoriasis (PsO)and psoriatic arthritis (PsA), and found that compared to rheumatoid arthritis (RA), psoriatic patients had up to a 3 fold higher risk of liver disease.